Veenstra D - Search Results

1

Veenstra D, Burke W. Veenstra D, et al. Public Health Genomics. 2009;12(3):131-3. doi: 10.1159/000189624. Epub 2009 Feb 10. Public Health Genomics. 2009. PMID: 19204414 Free PMC article. No abstract available.

2

Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?

Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, Veenstra DL. Oestreicher N, et al. Among authors: veenstra dl. Genet Med. 2005 Jul-Aug;7(6):380-9. doi: 10.1097/01.gim.0000170776.31248.75. Genet Med. 2005. PMID: 16024969 Free article.

3

Ancillary risk information and pharmacogenetic tests: social and policy implications.

Henrikson NB, Burke W, Veenstra DL. Henrikson NB, et al. Among authors: veenstra dl. Pharmacogenomics J. 2008 Apr;8(2):85-9. doi: 10.1038/sj.tpj.6500457. Epub 2007 May 8. Pharmacogenomics J. 2008. PMID: 17486108 Review.

4

Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes.

Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C. Veenstra DL, et al. Genet Med. 2007 Oct;9(10):695-704. doi: 10.1097/gim.0b013e318156dd07. Genet Med. 2007. PMID: 18073583 Free article.

5

Cytochrome p450 enzyme polymorphism frequency in indigenous and native american populations: a systematic review.

Jaja C, Burke W, Thummel K, Edwards K, Veenstra DL. Jaja C, et al. Community Genet. 2008;11(3):141-9. doi: 10.1159/000113876. Epub 2008 Mar 26. Community Genet. 2008. PMID: 18376110 Review.

6

A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications.

Garrison LP Jr, Carlson RJ, Carlson JJ, Kuszler PC, Meckley LM, Veenstra DL. Garrison LP Jr, et al. Drug Metab Rev. 2008;40(2):377-401. doi: 10.1080/03602530801952500. Drug Metab Rev. 2008. PMID: 18464050 Review.

7

Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation.

Salinger DH, Shen DD, Thummel K, Wittkowsky AK, Vicini P, Veenstra DL. Salinger DH, et al. Among authors: veenstra dl. Pharmacogenet Genomics. 2009 Dec;19(12):965-71. doi: 10.1097/FPC.0b013e3283333b80. Pharmacogenet Genomics. 2009. PMID: 19881396 Free PMC article.

8

Stakeholder perspectives on a risk-benefit framework for genetic testing.

Roth JA, Garrison LP Jr, Burke W, Ramsey SD, Carlson R, Veenstra DL. Roth JA, et al. Among authors: veenstra dl. Public Health Genomics. 2011;14(2):59-67. doi: 10.1159/000290452. Epub 2010 Apr 20. Public Health Genomics. 2011. PMID: 20407215 Free PMC article.

9

A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice.

Veenstra DL, Roth JA, Garrison LP Jr, Ramsey SD, Burke W. Veenstra DL, et al. Genet Med. 2010 Nov;12(11):686-93. doi: 10.1097/GIM.0b013e3181eff533. Genet Med. 2010. PMID: 20808229 Free PMC article.

10

Cost effectiveness of pharmacogenomics: a critical and systematic review.

Wong WB, Carlson JJ, Thariani R, Veenstra DL. Wong WB, et al. Pharmacoeconomics. 2010;28(11):1001-13. doi: 10.2165/11537410-000000000-00000. Pharmacoeconomics. 2010. PMID: 20936884 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

285 results

Search Page

Filters